×
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)

$12.90 Million in Sales Expected for Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) This Quarter

Last updated on Wednesday, January 12, 2022 | 2022 MarketBeat

Equities analysts predict that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) will announce $12.90 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Arcturus Therapeutics' earnings. The lowest sales estimate is $1.50 million and the highest is $43.40 million. Arcturus Therapeutics posted sales of $2.24 million during the same quarter last year, which would indicate a positive year over year growth rate of 475.9%. The firm is scheduled to report its next quarterly earnings report on Monday, March 7th.

According to Zacks, analysts expect that Arcturus Therapeutics will report full year sales of $20.03 million for the current year, with estimates ranging from $8.07 million to $49.97 million. For the next financial year, analysts anticipate that the company will post sales of $255.72 million, with estimates ranging from $189.40 million to $369.14 million. Zacks Investment Research's sales averages are a mean average based on a survey of sell-side research firms that follow Arcturus Therapeutics.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its quarterly earnings results on Monday, November 8th. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.40) by ($0.65). The business had revenue of $2.44 million for the quarter, compared to analysts' expectations of $26.70 million. Arcturus Therapeutics had a negative return on equity of 55.78% and a negative net margin of 2,227.82%. During the same quarter in the prior year, the company posted ($0.92) EPS.

Several research firms have issued reports on ARCT. Zacks Investment Research cut Arcturus Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday. Cantor Fitzgerald lifted their target price on Arcturus Therapeutics from $85.00 to $93.00 and gave the company an "overweight" rating in a report on Tuesday, November 16th. Finally, Barclays decreased their target price on Arcturus Therapeutics from $46.00 to $31.00 and set an "underweight" rating for the company in a report on Tuesday, November 9th. Seven analysts have rated the stock with a sell rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Sell" and an average target price of $52.29.


NASDAQ:ARCT opened at $33.51 on Wednesday. Arcturus Therapeutics has a one year low of $24.87 and a one year high of $89.18. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.19 and a current ratio of 6.19. The stock has a market cap of $883.36 million, a PE ratio of -4.46 and a beta of 2.66. The stock has a 50 day moving average price of $38.16 and a 200 day moving average price of $42.21.

In related news, COO Pad Chivukula sold 6,367 shares of the company's stock in a transaction that occurred on Wednesday, December 8th. The stock was sold at an average price of $40.00, for a total value of $254,680.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders sold 28,100 shares of company stock worth $1,168,100. Insiders own 12.20% of the company's stock.

A number of large investors have recently made changes to their positions in the business. Charles Schwab Investment Management Inc. raised its position in shares of Arcturus Therapeutics by 4.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 144,621 shares of the biotechnology company's stock worth $4,894,000 after buying an additional 6,095 shares during the period. Formidable Asset Management LLC raised its position in shares of Arcturus Therapeutics by 79.3% in the 2nd quarter. Formidable Asset Management LLC now owns 12,325 shares of the biotechnology company's stock worth $346,000 after buying an additional 5,450 shares during the period. Commonwealth Equity Services LLC raised its position in shares of Arcturus Therapeutics by 17.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 11,607 shares of the biotechnology company's stock worth $392,000 after buying an additional 1,758 shares during the period. Schonfeld Strategic Advisors LLC raised its position in shares of Arcturus Therapeutics by 22.5% in the 2nd quarter. Schonfeld Strategic Advisors LLC now owns 23,532 shares of the biotechnology company's stock worth $796,000 after buying an additional 4,324 shares during the period. Finally, Metropolitan Life Insurance Co NY raised its position in shares of Arcturus Therapeutics by 104,016.7% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 6,247 shares of the biotechnology company's stock worth $211,000 after buying an additional 6,241 shares during the period. Hedge funds and other institutional investors own 82.95% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings, Inc is a clinical-stage mRNA medicines and vaccines company, which focuses on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Featured Story: Percentage Decliners

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Arcturus Therapeutics (NASDAQ:ARCT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Arcturus Therapeutics right now?

Before you consider Arcturus Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.

While Arcturus Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.